Department of Nuclear Medicine (Treatment Center of Minimally Invasive Intervention and Radioactive Particles), First Affiliated Hospital of the Army Medical University, Chongqing, China.
Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of the Army Medical University, Chongqing, China.
Brachytherapy. 2023 Nov-Dec;22(6):851-857. doi: 10.1016/j.brachy.2023.05.006. Epub 2023 Aug 19.
To investigate the safety and efficacy of iodine-125 seed implantation in the treatment of abdomen-thorax desmoid tumors (DTs).
Data from 14 DT patients who received brachytherapy with iodine-125 seeds were retrospectively collected from 2014 to 2020. The operation was completed using CT guidance and the treatment plan system (TPS). The number of lesions and the target dosimetry parameters were recorded. After brachytherapy, the lesions were evaluated using response evaluation criteria in solid tumors (RECIST).
Fourteen patients with 18 lesions were enrolled in this study; eleven lesions were in the thorax, seven were in the abdomen, and the lesion gross tumor volume (GTV) was 82.10 cc (interquartile range [IQR]: 40.37, 203.42 cc). The median number of seeds was 88 (IQR: 35, 158), and the median prescription dose was 120 Gy (IQR: 115, 120 Gy). The D was 123 ± 16.7 Gy, the V was 97% (IQR: 95.00, 97.25%), and the V was 27% (IQR: 14.50, 33.00%). The median follow-up time for each lesion was 34 (IQR: 23, 67) months, and the local response rate was 100%. Following brachytherapy, the overall survival was 52.3 ± 30.72 months. One year after brachytherapy, one patient experienced persistent worsening of a brachial plexus injury; another received a ureteral stent. No brachytherapy-related complications were observed in the remaining patients.
Iodine-125 brachytherapy is a novel treatment option for DT of the abdomen and thorax. Although it is a safe and effective treatment, the radiation dose of iodine-125 brachytherapy for DT-embedded organs at risk must be investigated further.
探讨碘-125 种子植入治疗腹部-胸部腹壁间室肿瘤（DT）的安全性和有效性。
回顾性收集了 2014 年至 2020 年期间 14 例接受碘-125 种子近距离治疗的 DT 患者的数据。手术采用 CT 引导和治疗计划系统（TPS）完成。记录了病变的数量和靶区剂量学参数。近距离治疗后，采用实体瘤反应评估标准（RECIST）评估病变。
本研究共纳入 14 例 18 处病变患者；11 处病变位于胸部，7 处病变位于腹部，病变大体肿瘤体积（GTV）为 82.10 cc（四分位距[IQR]：40.37，203.42 cc）。种子中位数为 88 粒（IQR：35，158 粒），处方剂量中位数为 120 Gy（IQR：115，120 Gy）。D 为 123 ± 16.7 Gy，V 为 97%（IQR：95.00，97.25%），V 为 27%（IQR：14.50，33.00%）。每个病变的中位随访时间为 34（IQR：23，67）个月，局部反应率为 100%。近距离治疗后，总生存率为 52.3 ± 30.72 个月。1 例患者在近距离治疗后 1 年出现臂丛神经损伤持续加重，另 1 例患者接受了输尿管支架。其余患者未观察到与近距离治疗相关的并发症。
碘-125 近距离治疗是腹部和胸部 DT 的一种新的治疗选择。虽然碘-125 近距离治疗是一种安全有效的治疗方法，但必须进一步研究碘-125 近距离治疗对危险器官的剂量。
